@LighteningStron @ThePainTrader Also I read the book first and would 100% recommend to rather just skip the book and study the Discord. It's way more detailed and filled with tons of other information.
@LighteningStron @ThePainTrader For sure only 1 Mr. Price aka Pain. But for studying Wyckoff - other than Mr. Pain's Discord - I read Ruben Villahermosa's book "The Wyckoff methodology in depth"
Kudos to Muskaan Aggarwal! With an interest in immunology + oncology, she summarizes the science behind the Phase 3 trial, led by Dr. Linda Liau, @UCLANsgy, @JAMAOnc, "Dendritic Cell Vaccines: A New Frontier of Treatment for #GBM" @PennNSG#immunotherapy
https://t.co/scbkMDjKnN
$NWBO #DCVax-L trial results picked by the editorial board as 1 of the top / best advances - “News That Mattered”- during 2022 in the 1/19/2023 edition of Neurology Today: https://t.co/bXdj99sR08
$NWBO Patent granted on December 15, 2022 - MX/a/2016/005925 🇲🇽 Combinations of checkpoint inhibitors and therapeutics to treat cancer #DCVax-L
https://t.co/sky1kfPfBB…
Researchers at the @LifespanHlthSys Cancer Institute announce promising results in Phase III clinical trials for a vaccine to extend survival for patients with glioblastoma, now looking for @US_FDA approval. -SK #WPRO
3 minutes mark. Dr. Toms says Dr. Liau has a few 17/18 years survivors and he has a couple of 12 years survivors. What about the other centers? 😀Safe with Undeniable benefit = Approval. $NWBO https://t.co/NX95iVhEBp #cancer#GBM
Dr. Steven Toms of Brown University comments on Dr. Linda Liau #DCVax-L combo early trial results with PD-1 inhibitors, saying GBM patients survival rate at about 50%. This is great news for $NWBO: https://t.co/fppyPTd5su
☝🏼 This type of support by Wafik El-Deiry (discovered one of the most important cancer-related genes, WAF-1 / p21, now Director of Cancer Center at Brown University etc etc) blows away the whiny political science bs we’ve been hearing for years.
$NWBO
$NWBO
The Rhode Island news conference done by @wpri12 regarding the results of the #Dcvax trial.
Great to see US news coverage and not least the mention of the more than 50% efficacy of the current combo trial with DCVax-L and Keytruda done by UCLA.
https://t.co/xGNZOELqbG
This is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma❗️❗️❗️❗️
With existing standard of care treatments, patients typically survive for only about 15-17 months from diagnosis, with five-year survival from diagnosis only about 5%.